Rupal Desai

1.1k total citations
18 papers, 581 citations indexed

About

Rupal Desai is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rupal Desai has authored 18 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Rupal Desai's work include Cancer Genomics and Diagnostics (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and HER2/EGFR in Cancer Research (4 papers). Rupal Desai is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and HER2/EGFR in Cancer Research (4 papers). Rupal Desai collaborates with scholars based in United States, France and Australia. Rupal Desai's co-authors include Rajiv Raja, R. D. Patel, David Baunoch, Mark G. Erlander, Shirley Chu, Dennis C. Sgroi, Ranelle Salunga, Xiaojun Ma, Wei Wang and Wei Wang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Rupal Desai

18 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rupal Desai United States 11 414 195 161 142 137 18 581
Sandra J. Shin United States 15 400 1.0× 266 1.4× 152 0.9× 223 1.6× 25 0.2× 26 802
Kyungsoo Jung South Korea 13 299 0.7× 59 0.3× 224 1.4× 196 1.4× 29 0.2× 20 663
Ka‐Won Noh Germany 13 204 0.5× 52 0.3× 97 0.6× 92 0.6× 30 0.2× 22 402
Samira Lobo United Kingdom 5 136 0.3× 30 0.2× 209 1.3× 135 1.0× 80 0.6× 5 520
Martin Wartenberg Switzerland 10 290 0.7× 46 0.2× 134 0.8× 131 0.9× 23 0.2× 30 467
Takayuki Takahama Japan 14 265 0.6× 65 0.3× 125 0.8× 150 1.1× 15 0.1× 45 473
J.M. del Campo Spain 10 373 0.9× 63 0.3× 211 1.3× 72 0.5× 20 0.1× 17 639
D. Hungermann Germany 11 265 0.6× 136 0.7× 173 1.1× 196 1.4× 12 0.1× 23 555
Brett H. Simmons United States 8 201 0.5× 59 0.3× 257 1.6× 124 0.9× 9 0.1× 9 488
Allison Hills United Kingdom 10 416 1.0× 111 0.6× 424 2.6× 607 4.3× 13 0.1× 12 861

Countries citing papers authored by Rupal Desai

Since Specialization
Citations

This map shows the geographic impact of Rupal Desai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rupal Desai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rupal Desai more than expected).

Fields of papers citing papers by Rupal Desai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rupal Desai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rupal Desai. The network helps show where Rupal Desai may publish in the future.

Co-authorship network of co-authors of Rupal Desai

This figure shows the co-authorship network connecting the top 25 collaborators of Rupal Desai. A scholar is included among the top collaborators of Rupal Desai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rupal Desai. Rupal Desai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lindeman, Geoffrey J., Tharu M. Fernando, Rebecca Bowen, et al.. (2022). VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. Clinical Cancer Research. 28(15). 3256–3267. 49 indexed citations
2.
3.
Lindeman, Geoffrey J., Rebecca Bowen, Katarzyna J. Jerzak, et al.. (2021). Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).. Journal of Clinical Oncology. 39(15_suppl). 1004–1004. 23 indexed citations
4.
Morimoto, Alyssa, Julie Rae, Leslie W. Chinn, et al.. (2019). FRI0129 THE BTK INHIBITOR, FENEBRUTINIB, EFFECTIVELY MODULATES B AND MYELOID CELL BIOLOGY IN RHEUMATOID ARTHRITIS PATIENTS. Annals of the Rheumatic Diseases. 78. 733–734. 1 indexed citations
5.
Weekes, Colin D., Lee S. Rosen, Anna Capasso, et al.. (2018). Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 82(2). 339–351. 15 indexed citations
6.
Jarzabek, Monika A., William R. Proctor, Jennifer Vogt, et al.. (2018). Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer. PLoS ONE. 13(6). e0198099–e0198099. 8 indexed citations
7.
Asundi, Jyoti, Lisa Crocker, Jarrod R. Tremayne, et al.. (2015). An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clinical Cancer Research. 21(14). 3252–3262. 28 indexed citations
8.
Wilson, Timothy R., Yuanyuan Xiao, Jill M. Spoerke, et al.. (2014). Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Research and Treatment. 148(2). 315–325. 21 indexed citations
9.
Schleifman, Erica, Rachel Tam, Rajesh Patel, et al.. (2014). Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel. PLoS ONE. 9(3). e90761–e90761. 12 indexed citations
10.
Schleifman, Erica, Rupal Desai, Jill M. Spoerke, et al.. (2014). Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers. PLoS ONE. 9(2). e88401–e88401. 30 indexed citations
11.
Kadel, Edward E., Kimberly Walter, Rupal Desai, et al.. (2013). Abstract 4978: Lung cancers regulate the immune suppressor PD-L1 by multiple mechanisms, altering its role in tumor survival.. Cancer Research. 73(8_Supplement). 4978–4978. 1 indexed citations
12.
Powderly, John D., Hartmut Koeppen, F. Stephen Hodi, et al.. (2013). Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.. Journal of Clinical Oncology. 31(15_suppl). 3001–3001. 51 indexed citations
13.
Patel, Rajesh, Rachel Tam, Rupal Desai, et al.. (2013). Correction: Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel. PLoS ONE. 8(9). 6 indexed citations
14.
Patel, R. D., Rachel Tam, Rupal Desai, et al.. (2012). Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel. PLoS ONE. 7(12). e51153–e51153. 22 indexed citations
15.
Spoerke, Jill M., Carol O’Brien, Jenny Wu, et al.. (2012). Abstract 4821: Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors. Cancer Research. 72(8_Supplement). 4821–4821. 1 indexed citations
16.
Hollebecque, Antoine, Andrew R. Clamp, Laura Horsley, et al.. (2011). Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).. Molecular Cancer Therapeutics. 10(11_Supplement). B153–B153. 6 indexed citations
17.
Ma, Xiaojun, R. D. Patel, Ranelle Salunga, et al.. (2006). Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay.. PubMed. 130(4). 465–73. 156 indexed citations
18.
Ma, Xiaojun, R. D. Patel, Ranelle Salunga, et al.. (2006). Molecular Classification of Human Cancers Using a 92‐Gene Real-Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology & Laboratory Medicine. 130(4). 465–473. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra J. Shin Breakdown of academic impact, for papers by Kyungsoo Jung Breakdown of academic impact, for papers by Ka‐Won Noh Breakdown of academic impact, for papers by Samira Lobo Breakdown of academic impact, for papers by Martin Wartenberg Breakdown of academic impact, for papers by Takayuki Takahama Breakdown of academic impact, for papers by J.M. del Campo Breakdown of academic impact, for papers by D. Hungermann Breakdown of academic impact, for papers by Brett H. Simmons Breakdown of academic impact, for papers by Allison Hills
Rankless by CCL
2026